Status:
UNKNOWN
VItamin K Inhibition and NeurocoGnition (VIKING)
Lead Sponsor:
University Hospital, Angers
Conditions:
Neurocognitive Disorders
Eligibility:
All Genders
70+ years
Brief Summary
The primary objective of this study is to determine whether patients usually taking Vitamin K Antagonists (VKAs) exhibit a poorer global cognitive performance than control patients (matched on age, ge...
Detailed Description
VKAs are the most common drugs in the treatment and prophylaxis of thromboembolic events in older adults. Their action is mediated by decrease in the bioavailability of the active form of vitamin K. H...
Eligibility Criteria
Inclusion
- Age 70 years and over
- To be seen in consultation or day hospital in the department of geriatrics from 01/01/2015 to 31/12/2016
- Exposed :
- Patients who have been taking VKA for at least 3 months for atrial fibrillation or pulmonary embolism, with INR between 2 and 3
- Non-exposed:
- Patients who have been taking DOAC for at least 3 months for atrial fibrillation or pulmonary embolism
- Matched on age (± 5 years), gender and indication for anticoagulation
Exclusion
- Severe kidney failure (creatinine clearance \< 30 mL/min)
- Language other than French
Key Trial Info
Start Date :
September 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03276377
Start Date
September 1 2017
End Date
September 1 2018
Last Update
September 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Angers University Hospital
Angers, France, 49933